Shares of Knight Therapeutics Inc. (TSE:GUD – Get Free Report) hit a new 52-week high during trading on Tuesday . The stock traded as high as C$6.23 and last traded at C$6.22, with a volume of 30936 shares traded. The stock had previously closed at C$6.20.
Analyst Ratings Changes
Several brokerages have commented on GUD. Stifel Canada raised shares of Knight Therapeutics from a “hold” rating to a “strong-buy” rating in a research report on Monday, August 12th. Stifel Nicolaus raised shares of Knight Therapeutics from a “hold” rating to a “buy” rating and boosted their price target for the company from C$5.75 to C$6.75 in a research report on Tuesday, August 13th.
Check Out Our Latest Stock Analysis on Knight Therapeutics
Knight Therapeutics Trading Down 0.2 %
Knight Therapeutics (TSE:GUD – Get Free Report) last issued its quarterly earnings data on Thursday, August 8th. The company reported C($0.02) EPS for the quarter, missing the consensus estimate of C$0.03 by C($0.05). The firm had revenue of C$95.57 million for the quarter, compared to analysts’ expectations of C$89.83 million. Knight Therapeutics had a negative net margin of 6.28% and a negative return on equity of 2.70%.
Insider Activity at Knight Therapeutics
In related news, Senior Officer Amal Khouri sold 10,000 shares of the business’s stock in a transaction that occurred on Thursday, July 11th. The shares were sold at an average price of C$5.70, for a total transaction of C$57,000.00. Over the last 90 days, insiders sold 30,500 shares of company stock valued at $174,744. Corporate insiders own 45.60% of the company’s stock.
Knight Therapeutics Company Profile
Knight Therapeutics Inc develops, manufactures, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices worldwide. It offers Tafasitamab for relapsed or refractory diffuse large B-cell lymphoma; Pemigatinib for metastatic cholangiocarcinoma; Akynzeo for prevention of chemotherapy-induced acute and delayed nausea and vomiting; Aloxi for prevention of acute nausea and vomiting associated with emetogenic cancer chemotherapy; Fostamatinib for chronic immune thrombocytopenia; Nerlynx for extended adjuvant breast cancer and metastatic breast cancer; Trelstar for advanced prostate cancer; Vidaza for myelodysplastic syndrome; Abraxane for metastatic pancreatic cancer; Halaven for metastatic breast cancer and soft tissue sarcoma; and Lenvima for advanced renal cell cancer and for differentiated thyroid cancer and unresectable hepatocellular carcinoma.
Featured Articles
- Five stocks we like better than Knight Therapeutics
- CD Calculator: Certificate of Deposit Calculator
- Edgewise Therapeutics Soars 50%: Key Reasons Behind the Surge
- Following Congress Stock Trades
- How the Fed’s Rate Cut Could Supercharge These 3 ETFs
- Low PE Growth Stocks: Unlocking Investment Opportunities
- Microsoft Stock: 3 Reasons It’s Ready to Crush Q4
Receive News & Ratings for Knight Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Knight Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.